Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM. García F, et al. J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35. doi: 10.1097/00042560-200009010-00004. J Acquir Immune Defic Syndr. 2000. PMID: 11064501 Clinical Trial.
Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status.
Moreno S, Jarrin I, Iribarren JA, Perez-Elías MJ, Viciana P, Parra-Ruiz J, Gomez-Sirvent JL, Lopez-Aldeguer J, Gutierrez F, Blanco JR, Vidal F, Leal M, Rodríguez Arenas MA, Del Amo J; CoRIS-MD. Moreno S, et al. Int J Tuberc Lung Dis. 2008 Dec;12(12):1393-400. Int J Tuberc Lung Dis. 2008. PMID: 19017448
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients; Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN. Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, et al. Lancet. 2010 Jul 31;376(9738):340-5. doi: 10.1016/S0140-6736(10)60932-4. Epub 2010 Jul 15. Lancet. 2010. PMID: 20638118 Free PMC article.
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
HIV-CAUSAL Collaboration; Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA. HIV-CAUSAL Collaboration, et al. Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001. Ann Intern Med. 2011. PMID: 21502648 Free PMC article.
Drug resistance mutations in patients infected with HIV-2 living in Spain.
Treviño A, de Mendoza C, Caballero E, Rodríguez C, Parra P, Benito R, Cabezas T, Roc L, Aguilera A, Soriano V; HIV-2 Spanish Study Group. Treviño A, et al. J Antimicrob Chemother. 2011 Jul;66(7):1484-8. doi: 10.1093/jac/dkr164. Epub 2011 May 10. J Antimicrob Chemother. 2011. PMID: 21558334
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL; Study 145 Team. Molina JM, et al. Lancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3. Epub 2011 Oct 18. Lancet Infect Dis. 2012. PMID: 22015077 Clinical Trial.
Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain.
Treviño A, Aguilera A, Caballero E, Benito R, Parra P, Eiros JM, Hernandez A, Calderón E, Rodríguez M, Torres A, García J, Ramos JM, Roc L, Marcaida G, Rodríguez C, Trigo M, Gomez C, de Lejarazu RO, de Mendoza C, Soriano V; HTLV Spanish Study Group. Treviño A, et al. Virol J. 2012 Mar 23;9:71. doi: 10.1186/1743-422X-9-71. Virol J. 2012. PMID: 22444832 Free PMC article.
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration. del Amo J, et al. Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28. Clin Infect Dis. 2012. PMID: 22460971 Free PMC article.
105 results